ABC of monitoring drug therapy. Digoxin.

ABC of monitoring drug therapy. Digoxin.

Opis bibliograficzny
Główni autorzy:	Aronson, J, Hardman, M
Format:	Journal article
Język:	English
Wydane:	1992

Podobne zapisy

ABC of monitoring drug therapy. Why monitor drug therapy?
od: Aronson, J, i wsp.
Wydane: (1992)

ABC of monitoring drug therapy. Patient compliance.
od: Aronson, J, i wsp.
Wydane: (1992)

ABC of monitoring drug therapy. Theophylline.
od: Aronson, J, i wsp.
Wydane: (1992)

ABC of monitoring drug therapy. Phenytoin.
od: Aronson, J, i wsp.
Wydane: (1992)

ABC of monitoring drug therapy. Measuring plasma drug concentrations.
od: Aronson, J, i wsp.
Wydane: (1992)

Monitoring digoxin therapy. The use of plasma digoxin concentration measurements in the diagnosis of digoxin toxicity.
od: Aronson, J, i wsp.
Wydane: (1978)

Monitoring digoxin therapy: III. How useful are the nomograms?
od: Aronson, J
Wydane: (1978)

ABC of monitoring drug therapy. Lithium.
od: Aronson, J, i wsp.
Wydane: (1992)

ABC of monitoring drug therapy. Cyclosporin.
od: Reynolds, D, i wsp.
Wydane: (1992)

Monitoring digoxin therapy: II. Determinants of the apparent volume of distribution.
od: Aronson, J, i wsp.
Wydane: (1977)

ABC of monitoring drug therapy. Aminoglycoside antibiotics.
od: Aronson, J, i wsp.
Wydane: (1992)

Digoxin revisited.
od: Aronson, J
Wydane: (1998)

Drug therapy monitoring (TDM) of Digoxin: safety and efficacy review
od: Rony Abdi Syahputra, i wsp.
Wydane: (2022-04-01)

ABC of monitoring drug therapy. Making the most of plasma drug concentration measurements.
od: Reynolds, D, i wsp.
Wydane: (1993)

Interaction of digoxin with quinine.
od: Aronson, J, i wsp.
Wydane: (1981)

MONITORING OF SERUM DIGOXIN CONCENTRATION AND SAFETY OF THERAPY WITH DIGOXIN IN PATIENTS WITH ATRIAL FIBRILLATION
od: S. F. Zadvorev, i wsp.
Wydane: (2018-05-01)

Clinical pharmacokinetics of digoxin 1980.
od: Aronson, J
Wydane: (1980)

Monitoring digoxin therapy: I. Plasma concentrations and an in vitro assay of tissue response.
od: Aronson, J, i wsp.
Wydane: (1977)

The characteristics of the binding of 12-alpha-[3H]-digoxin to the membranes of intact human erythrocytes: relevance to digoxin therapy.
od: Ford, A, i wsp.
Wydane: (1979)

DIAGNOSING DIGOXIN TOXICITY BY COMBINED MEASUREMENT OF PLASMA DIGOXIN CONCENTRATIONS AND ERYTHROCYTIC RB-86 UPTAKE
od: Aronson, J, i wsp.
Wydane: (1983)

Indications for the measurement of plasma digoxin concentrations.
od: Aronson, J
Wydane: (1983)

Digoxin-like factor in infants of diabetic mothers not receiving digoxin therapy
od: M Yurdakök, i wsp.
Wydane: (1989-10-01)

Appropriateness of digoxin level monitoring
od: MR Mordasini, i wsp.
Wydane: (2002-09-01)

The use of colour vision measurement in the diagnosis of digoxin toxicity.
od: Aronson, J, i wsp.
Wydane: (1980)

In vivo cation transport during short-term and long-term digoxin therapy.
od: Boon, N, i wsp.
Wydane: (1986)

EVIDENCE THAT CATION-TRANSPORT INVIVO IS INHIBITED BY SHORT-TERM BUT NOT LONG-TERM DIGOXIN THERAPY
od: Boon, N, i wsp.
Wydane: (1984)

The acute changes seen in cardiac glycoside receptor sites, 86rubidium uptake and intracellular sodium concentrations in the erythrocytes of patients during the early phases of digoxin therapy are not found during chronic therapy: pharmacological and therapeutic implications for chronic digoxin therapy.
od: Ford, A, i wsp.
Wydane: (1979)

ERYTHROCYTIC DIGOXIN RECEPTOR NUMBERS AND ACTIVITY - RELATION TO CLINICAL CHANGES FOLLOWING DIGOXIN WITHDRAWAL AFTER LONG-TERM TREATMENT FOR HEART-FAILURE IN SINUS RHYTHM
od: Pugh, S, i wsp.
Wydane: (1982)

THE EFFECT OF DIGOXIN ON THE INVIVO DISPOSITION OF AN ORAL LOAD OF RUBIDIUM CHLORIDE
od: Aronson, J, i wsp.
Wydane: (1982)

Characterizing Utilization and Outcomes of Digoxin Immune Fab for Digoxin Toxicity
od: Sophia Sheikh, i wsp.
Wydane: (2024-06-01)

Therapeutic drug monitoring of digoxin in cardiac heart failure outpatients: comparisons of two analytical methods
od: Isabel Cristina Medeiros Barros, i wsp.
Wydane: (2014-01-01)

Pharmacokinetic monitoring of chronic treatment with digoxin from Primary Health Care
od: Emma M García-Iranzo, i wsp.
Wydane: (2017-07-01)

Effects of Age, Gender, and Comorbid Diseases on Serum Digoxin Levels During Digoxin Treatment
od: Zeynep ÖZTÜRK, i wsp.
Wydane: (2018-01-01)

Serum digoxin concentrations in dogs with atrial fibrillation under long term digoxin treatment
od: Antonella Colella, i wsp.
Wydane: (2022-06-01)

Monitoring drug therapy.
od: Buclin, T, i wsp.
Wydane: (2012)

Neglected facts in digoxin intoxication
od: Sibel Ocak Serin
Wydane: (2017-06-01)

Association between the number of coadministered P-glycoprotein inhibitors and serum digoxin levels in patients on therapeutic drug monitoring
od: Michaëlsson Karl, i wsp.
Wydane: (2004-04-01)

Treatment with Digoxin – is it a clinical challenge? A Retrospective Analysis of Hospitalizations due to Digoxin intoxication
od: Marcin Wais, i wsp.
Wydane: (2024-04-01)

Severe digoxin intoxication: A case report of the use of digoxin-specific Fab antibody fragments
od: Tadej Petreski, i wsp.
Wydane: (2023-08-01)

Ten Years of Experience in Treating Patients With Digoxin Toxicity Without Using Digoxin Fab Antibody
od: Farzad Gheshlagh, i wsp.
Wydane: (2021-01-01)